Quidel Corporation Applauds Biden Administration Plan to Expand COVID-19 Testing
March 18 2021 - 6:00PM
Business Wire
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider
of rapid diagnostic testing solutions, cellular-based virology
assays and molecular diagnostic systems, today announced its
support for the Biden Administration’s plan to expand COVID-19
testing in schools, underserved communities, rural areas and other
settings that have been gravely impacted by the pandemic.
“Quidel applauds the Biden Administration’s urgent and
comprehensive approach to bringing the benefits of rapid, routine
and equitable coronavirus testing to America’s classrooms,
underserved communities and rural areas,” said Douglas Bryant,
president and CEO of Quidel Corporation. “Frequent testing has
proven to be a critical tool for both empowering people to take
charge of their own health and allowing large institutions,
businesses, sports and entertainment venues and enumerable other
aspects of society to reopen safely and remain so.”
“Our mission at Quidel has always been to democratize access to
frequent, affordable and highly accurate COVID-19 testing, and we
expect the Administration’s American Rescue Plan for testing will
turbocharge efforts all across the diagnostics industry to get
everyone screened so the virus and any variants can be stopped,
tracked and traced in real time,” Mr. Bryant noted. “We are
approaching the inflection point where frequent at-home, in-school
and on-site testing of asymptomatic people at scale can give us
greater peace of mind to see our families, dine out and
travel.”
Quidel recently received Emergency Use Authorization (EUA) from
the FDA for its QuickVue® At-Home COVID-19 Test, an easy-to-use
test that provides results to symptomatic patients in ten minutes
with a doctor’s prescription. The company is seeking an EUA for
over-the-counter (OTC) sale of the QuickVue® At-Home COVID-19 Test
to symptomatic and asymptomatic consumers without a prescription.
Quidel is currently building out a new manufacturing facility in
Carlsbad, CA dedicated to the production of Quidel’s popular
QuickVue® line of products. The 128,000 square foot facility will
be the company’s highest-volume production plant in the world and
is expected to produce 600 million QuickVue® rapid antigen tests
for the detection and diagnosis of COVID-19 infections.
Visit www.quickvueathome.com for more information.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of
diagnostic solutions at the point of care, delivering a continuum
of rapid testing technologies that further improve the quality of
health care throughout the globe. An innovator for over 40 years in
the medical device industry, Quidel pioneered the first FDA-cleared
point-of-care test for influenza in 1999 and was the first to
market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted
brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s
comprehensive product portfolio includes tests for a wide range of
infectious diseases, cardiac and autoimmune biomarkers, as well as
a host of products to detect COVID-19. With products made in
America, Quidel’s mission is to provide patients with immediate and
frequent access to highly accurate, affordable testing for the good
of our families, our communities and the world. For more
information about Quidel, visit quidel.com.
View our story told by our people at
www.quidel.com/ourstory.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the federal securities laws that involve material
risks, assumptions and uncertainties. Many possible events or
factors could affect our future results and performance, such that
our actual results and performance may differ materially from those
that may be described or implied in the forward-looking statements.
As such, no forward-looking statement can be guaranteed.
Differences in actual results and performance may arise as a result
of a number of factors including, without limitation: the impact
and duration of the COVID-19 global pandemic; competition from
other providers of diagnostic products; our ability to accurately
forecast demand for our products and products in development,
including in new market segments; our ability to develop new
technologies, products and markets and to commercialize new
products; our reliance on sales of our COVID-19 and influenza
diagnostic tests; our reliance on a limited number of key
distributors; quantity of our product in our distributors’
inventory or distribution channels; changes in the buying patterns
of our distributors; the financial soundness of our customers and
suppliers; lower than anticipated market penetration of our
products; third-party reimbursement policies and potential cost
constraints; our ability to meet demand for our products;
interruptions, delays or shortages in the supply of raw materials,
components and other products and services; failures in our
information technology and storage systems; our exposure to data
corruption, cyber-based attacks, security breaches and privacy
violations; international risks, including but not limited to,
economic, political and regulatory risks; continuing worldwide
political and social uncertainty; our development, acquisition and
protection of proprietary technology rights; intellectual property
risks, including but not limited to, infringement litigation; the
loss of Emergency Use Authorizations for our COVID-19 products and
failures or delays in receipt of reviews or regulatory approvals,
clearances or authorizations for new products or related to
currently-marketed products by the U.S. Food and Drug
Administration (the “FDA”) or other regulatory authorities or loss
of any previously received regulatory approvals, clearances or
authorizations or other adverse actions by regulatory authorities;
our contracts with government entities involve future funding,
compliance and possible sanctions risks; product defects; changes
in government policies and regulations and compliance risks related
thereto; our ability to manage our growth strategy and successfully
identify, acquire and integrate potential acquisition targets or
technologies and our ability to obtain financing; our acquisition
of Alere’s Triage® business presents certain risks to our business
and operations; the level of our deferred payment obligations; our
exposure to claims and litigation that could result in significant
expenses and could ultimately result in an unfavorable outcome for
us, including the ongoing litigation between us and Beckman
Coulter, Inc.; we may need to raise additional funds to finance our
future capital or operating needs; our debt, deferred and
contingent payment obligations; competition for and loss of
management and key personnel; business risks not covered by
insurance; changes in tax rates and exposure to additional tax
liabilities or assessments; and provisions in our charter documents
and Delaware law that might delay or impede stockholder actions
with respect to business combinations or similar transactions.
Forward-looking statements typically are identified by the use of
terms such as “may,” “will,” “should,” “might,” “expect,”
“anticipate,” “estimate,” “plan,” “intend,” “goal,” “project,”
“strategy,” “future,” and similar words, although some
forward-looking statements are expressed differently. The risks
described in reports and registration statements that we file with
the Securities and Exchange Commission from time to time, should be
carefully considered, including those discussed in Item 1A, “Risk
Factors” and elsewhere in our Annual Report on Form 10-K for the
year ended December 31, 2020 and in our subsequent Quarterly
Reports on Form 10-Q. You are cautioned not to place undue reliance
on these forward-looking statements, which reflect management’s
analysis only as of the date of this press release. Except as
required by law, we undertake no obligation to publicly release any
revision or update of these forward-looking statements, whether as
a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210318006003/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024